The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials
Open accessAbstract
Purpose To estimate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Design Cohort within a clinical trial.Participants Participants included in CATT.Methods A total of 1185 CATT participants were randomly assigned to ranibizumab or bevacizumab treatment and to 3 treatment regimens. Participants were released from protocol treatment at 2 years and examined at approximately 5 years (N = 647). Two masked graders assessed the presence and size of GA in digital color photographs (CPs) and fluorescein angiograms (FAs) taken at baseline and years 1, 2, and 5. Cox proportional hazard models were used to identify risk factors for incidence of GA. Annual change in the square root of the total area of GA was the measure of growth. Multivariate linear mixed models including baseline demographic, treatment, and ocular characteristics on CP/FA and optical coherence tomography (OCT) as candidate risk factors were used to estimate adjusted growth rates, standard errors (SEs), and 95% confidence intervals (CIs).Main outcome measures Geographic atrophy incidence and growth rate.Results Among the 1011 participants who did not have GA at baseline and had follow-up images gradable for GA, the cumulative incidence was 12% at 1 year, 17% at 2 years, and 38% at 5 years. At baseline, older age, hypercholesterolemia, worse visual acuity, larger choroidal neovascularization (CNV) area, retinal angiomatous proliferation (RAP) lesion, GA in the fellow eye, and intraretinal fluid were associated with a higher risk of incident GA. Thicker subretinal tissue complex and presence of subretinal fluid were associated with less GA development. The overall GA growth rate was 0.33 mm/year (SE, 0.02 mm/year). Eyes treated with ranibizumab in the first 2 years of the clinical trial had a higher growth rate than eyes treated with bevacizumab (adjusted growth rate, 0.38 vs. 0.28 mm/year; P = 0.009). Geographic atrophy in the fellow eye, hemorrhage, and absence of sub-retinal pigment epithelium fluid at baseline were associated with a higher growth rate.Conclusions Development of GA is common 5 years after initiating therapy. Several risk factors identified at 2 years of follow-up persist at 5 years of follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While long-term follow up of geographic atrophy after anti-VEGF therapy, more recently referred to as macular atrophy, has been described, long term follow-up of scars after the initiation of anti-VEGF therapy has not received much attention.10,11”
From Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,154
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group* (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,783
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Self-citationSeven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Self-citationRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Self-citationRelationship between RPE and Choriocapillaris in Age-Related Macular Degeneration
McLeod, D. S., Grebe, R. R., Bhutto, I. A., Merges, C. A., Baba, T., & Lutty, G. A. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3639 · Cited by 568
Cited by
Sorted by citations
Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,154
Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT
Sadda, S. R., Guymer, R. H., Holz, F. G., Schmitz-Valckenberg, S., Curcio, C. A., Bird, A. C., Blodi, B. A., Bottoni, F. G., Chakravarthy, U., Chew, E. Y., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.09.028 · Cited by 932
Self-citationLiao, D. S., Grossi, F. V., Mehdi, D. E., Gerber, M. R., Brown, D. M., Heier, J. S., Wykoff, C. C., Singerman, L. J., Abraham, P., Graßmann, F., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.07.011 · Cited by 566
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
Jaffe, G. J., Westby, K., Csaky, K. G., Monés, J., Pearlman, J. A., Patel, S. S., Joondeph, B. C., Randolph, J. C., Masonson, H., & Rezaei, K. A. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.027 · Cited by 494
Self-citationAge-Related Macular Degeneration
Thomas, C. J., Mirza, R. G., & Gill, M. K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.01.003 · Cited by 490
Risk factors for progression of age‐related macular degeneration
Heesterbeek, T. J., Lorés‐Motta, L., Hoyng, C. B., Lechanteur, Y. T. E., & den Hollander, A. I. (2020) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12675 · Cited by 399
Guymer, R. H., Markey, C. M., McAllister, I. L., Gillies, M. C., Hunyor, A. P., Arnold, J. J., Chang, A., Syed, A., Broadhead, G., Pham, T., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.025 · Cited by 317
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K. B., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 280
Rakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00345-1 · Cited by 189
Evans, R. N., Reeves, B. C., Maguire, M. G., Martin, D. F., Muldrew, A., Peto, T., Rogers, C., & Chakravarthy, U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.3001 · Cited by 145
Self-citationLi, E., Donati, S., Lindsley, K. B., Krzystolik, M. G., & Virgili, G. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012208.pub2 · Cited by 143
Gillies, M. C., Hunyor, A. P., Arnold, J., Guymer, R. H., Wolf, S., Ng, P., Pecheur, F. L., & McAllister, I. L. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6776 · Cited by 129
Gemenetzi, M. K., Lotery, A. J., & Patel, P. J. (2016) · Eye · doi:10.1038/eye.2016.208 · Cited by 134
Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Rosenfeld, P. J., Dugel, P. U., Holz, F. G., Heier, J. S., Pearlman, J. A., Novack, R. L., Csaky, K. G., Koester, J. M., Gregory, J. K., & Kubota, R. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.03.059 · Cited by 123
Daniel, E., Pan, W., Ying, G.-S., Kim, B. J., Grunwald, J. E., Ferris, F. L., Jaffe, G. J., Toth, C. A., Martin, D. F., Fine, S. L., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.004 · Cited by 119
“Although long-term follow-up of geographic atrophy after anti-VEGF therapy, more recently referred to as “macular atrophy,” has been described, longterm follow-up of scars after the initiation of anti-VEGF therapy has not received much attention.(10,11) The original CATT clinical trial was designed to assess differenc…”
BackgroundSelf-citationInflammatory cytokines in highly myopic eyes
Yuan, J., Wu, S., Wang, Y., Pan, S., Wang, P., & Cheng, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-39652-x · Cited by 102
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Khachigian, L. M., Liew, G., Teo, K. Y. C., Wong, T. Y., & Mitchell, P. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03937-7 · Cited by 98
Choriocapillaris Degeneration in Geographic Atrophy
Sohn, E. H., Flamme‐Wiese, M. J., Whitmore, S. S., Workalemahu, G., Marneros, A. G., Boese, E. A., Kwon, Y. H., Wang, K., Abràmoff, M. D., Tucker, B. A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.005 · Cited by 83
DeCroos, F. C., Reed, D. C., Adam, M. K., Salz, D. A., Gupta, O. P., Ho, A. C., & Regillo, C. D. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.06.002 · Cited by 81
Martín, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.019 · Cited by 76
Self-citationAnti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better
Usui‐Ouchi, A., & Friedlander, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129862 · Cited by 73
Neurovascular regulation in diabetic retinopathy and emerging therapies
Ji, L., Tian, H., Webster, K. A., & Li, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03893-9 · Cited by 76
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Yang, S., Li, T., Jia, H., Gao, M., Li, Y., Wan, X., Huang, Z., Li, M., Zhai, Y., Li, X., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2177 · Cited by 71
Toma, C., Cillà, S. D., Palumbo, A., Garhwal, D. P., & Grossini, E. (2021) · Antioxidants · doi:10.3390/antiox10050653 · Cited by 67
Kuppermann, B. D., Patel, S. S., Boyer, D. S., Augustin, A. J., Freeman, W. R., Kerr, K. J., Guo, Q., Schneider, S., López, F. J., & on behalf of the Brimo DDS Gen 1 Study Group (2020) · Retina · doi:10.1097/iae.0000000000002789 · Cited by 65
Sadda, S. R., Abdelfattah, N. S., Lei, J., Shi, Y., Marion, K. M., Morgenthien, E. A., Gune, S., & Balasubramanian, S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.031 · Cited by 67
Novel Programmed Cell Death as Therapeutic Targets in Age-Related Macular Degeneration?
Yang, M., So, K., Lam, W., & Lo, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197279 · Cited by 63
Chae, J., Jang, H., Son, C., Park, C., Choi, H., Jin, S., Lee, H., Lee, H., Ryu, J., Kim, N., et al. (2021) · GeroScience · doi:10.1007/s11357-021-00457-4 · Cited by 64
Sadda, S. R., Guymer, R. H., Monés, J., Tufail, A., & Jaffe, G. J. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.11.010 · Cited by 61
Self-citationTeo, K. Y. C., Joe, A. W., Nguyen, V., Invernizzi, A., Arnold, J., Barthelmes, D., & Gillies, M. C. (2020) · Retina · doi:10.1097/iae.0000000000002779 · Cited by 60
Mathis, T., Holz, F. G., Sivaprasad, S., Yoon, Y. H., Eter, N., Chen, L.-J., Koh, A. C., de Souza, E. C., & Staurenghi, G. (2022) · Eye · doi:10.1038/s41433-022-02231-y · Cited by 57
Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials
Ying, G., Maguire, M. G., Pan, W., Grunwald, J. E., Daniel, E., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., & Martín, D. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.10.003 · Cited by 59
Self-citationLiu, J., Shen, M., Laiginhas, R., Herrera, G., Li, J., Shi, Y., Hiya, F. E., Trivizki, O., Waheed, N. K., Chung, C. Y., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.03.012 · Cited by 56
Age-Related Macular Degeneration Preferred Practice Pattern®
Vemulakonda, G. A., Bailey, S. T., Kim, S. J., Kovach, J. L., Lim, J. I., Ying, G., & Flaxel, C. J. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.12.018 · Cited by 56
Self-citationMiwa, Y., Hoshino, Y., Shoda, C., Jiang, X., Tsubota, K., & Kurihara, T. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.008 · Cited by 52
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
Patel, P. N., & Sheth, V. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112436 · Cited by 46
Gune, S., Abdelfattah, N. S., Karamat, A., Balasubramanian, S., Marion, K. M., Morgenthien, E. A., & Sadda, S. R. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.030 · Cited by 44
Aberrant Lipid Metabolism and Complement Activation in Age-Related Macular Degeneration
Tang, S., Yang, J., Xiao, B., Wang, Y., Lei, Y., Lai, D., & Qiu, Q. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.12.20 · Cited by 48
Sivaprasad, S., Banister, K., Azuara‐Blanco, A., Goulão, B., Cook, J. A., Hogg, R. E., Scotland, G., Heimann, H., Lotery, A. J., Ghanchi, F. D., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.07.025 · Cited by 42
Xia, W., Li, C., Chen, Q., Huang, J., Zhao, Z., Liu, P., Xu, K., Li, L., Hu, F., Zhang, S., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.022 · Cited by 42
MicroRNAs and the HIF/VEGF axis in ocular neovascular diseases
Plastino, F., Pesce, N. A., & André, H. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14845 · Cited by 42
Cimaglia, G., Votruba, M., Morgan, J. E., André, H., & Williams, P. A. (2020) · Nutrients · doi:10.3390/nu12092871 · Cited by 40
Kiss, S., Oresic Bender, K., Grishanin, R. N., Hanna, K. M., Nieves, J. D., Sharma, P., Nguyen, A. T., Rosario, R. J., Greengard, J. S., Gelfman, C. M., et al. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.1.34 · Cited by 36
Atrophy in Neovascular Age-Related Macular Degeneration
Domalpally, A., Danis, R. P., Trane, R. M., Blodi, B. A., Clemons, T. E., & Chew, E. Y. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.04.009 · Cited by 36
Siedlecki, J., Fischer, C., Schworm, B., Kreutzer, T. C., Luft, N., Kortuem, K., Schumann, R. G., Wolf, A., & Priglinger, S. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-64901-9 · Cited by 34
Longer-acting treatments for neovascular age-related macular degeneration—present and future
Iglicki, M., González, D. P., Loewenstein, A., & Zur, D. (2021) · Eye · doi:10.1038/s41433-020-01309-9 · Cited by 33
Nguyen, V., Barthelmes, D., & Gillies, M. C. (2021) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13949 · Cited by 32
Kuroda, Y., Yamashiro, K., Ooto, S., Tamura, H., Oishi, A., Nakanishi, H., Miyata, M., Hata, M., Takahashi, A., Wakazono, T., et al. (2017) · Retina · doi:10.1097/iae.0000000000001765 · Cited by 32
Sreekumar, P. G., & Kannan, R. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101663 · Cited by 32
Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
Montesel, A., Bucolo, C., Sallo, F. B., & Eandi, C. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720345 · Cited by 32
New Treatment Modalities for Neovascular Age-Related Macular Degeneration
Schlottmann, P. G., Alezzandrini, A., Zas, M., Rodriguez, F. J., Luna, J. D., & Wu, L. (2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017258 · Cited by 30
Buonfiglio, F., Korb, C. A., Stoffelns, B. M., Pfeiffer, N., & Gericke, A. (2024) · Aging and Disease · doi:10.14336/ad.2024.0124 · Cited by 35
Roles of Hypoxia Response in Retinal Development and Pathophysiology
Kurihara, T. (2017) · The Keio Journal of Medicine · doi:10.2302/kjm.2017-0002-ir · Cited by 27
Thiele, S., Pfau, M., Larsen, P. P., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23315 · Cited by 26
Daniel, E., Ying, G., Kim, B. J., Toth, C. A., Ferris, F. L., Martin, D. F., Grunwald, J. E., Jaffe, G. J., Dunaief, J. L., Pan, W., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.020 · Cited by 26
Self-citationGreenlee, T. E., Wang, V. Y., Kang, H., Ohlhausen, M. E., Chen, A. X., Hom, G. L., Conti, T. F., Briskin, I. N., Babiuch, A. S., & Singh, R. P. (2020) · Retina · doi:10.1097/iae.0000000000002888 · Cited by 26
Aslanis, S., Amrén, U., Lindberg, C., & Epstein, D. L. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.03.010 · Cited by 27
Freund, K. B., Staurenghi, G., Jung, J. J., Zweifel, S. A., Cozzi, M., Hill, L., Blotner, S. D., Tsuboi, M., & Gune, S. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05586-w · Cited by 26
Toth, C. A., Tai, V., Pistilli, M., Chiu, S. J., Winter, K. P., Daniel, E., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Ying, G., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.11.011 · Cited by 25
Self-citationZarbin, M. A., Hill, L., Maunz, A., Gliem, M., & Stoilov, I. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318688 · Cited by 25
Core, J. Q., Pistilli, M., Daniel, E., Grunwald, J. E., Toth, C. A., Jaffe, G. J., Hua, P., Martin, D. F., Ying, G., & Maguire, M. G. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.06.003 · Cited by 25
Self-citationHuang, Y.-H., Kuo, C., Peng, I., Chang, Y.-S., Tseng, S.-H., Conway, E. M., & Wu, H. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03950-3 · Cited by 26
Sadda, S. R., Holekamp, N. M., Sarraf, D., Ebraheem, A., Fan, W., Hill, L., Blotner, S., Spicer, G. J., & Gune, S. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05716-4 · Cited by 25
Cheng, Q. E., Gao, J., Kim, B. J., & Ying, G. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.08.018 · Cited by 25
Self-citationIncidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration
Christakis, P. G., Agrón, E., Klein, M. L., Clemons, T. E., Campbell, J. P., Ferris, F. L., Chew, E. Y., & Keenan, T. D. L. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.11.016 · Cited by 25
Finn, A. P., Pistilli, M., Tai, V., Daniel, E., Ying, G., Maguire, M. G., Grunwald, J. E., Martin, D. F., Jaffe, G. J., & Toth, C. A. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.11.002 · Cited by 23
Self-citationNesper, P. L., Lutty, G. A., & Fawzi, A. A. (2017) · Retina · doi:10.1097/iae.0000000000001863 · Cited by 23
Fellow Eye Status Is a Biomarker for the Progression Rate of Geographic Atrophy
Shen, L. L., Liu, F., Nardini, H. K. G., & Priore, L. V. D. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.11.013 · Cited by 23
Core, J. Q., Pistilli, M., Hua, P., Daniel, E., Grunwald, J. E., Toth, C. A., Jaffe, G. J., Martin, D. F., Maguire, M. G., Ying, G., et al. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.024 · Cited by 23
Self-citationStarr, M. R., Kung, F. F., Mejia, C. A., Bui, Y. T., & Bakri, S. J. (2020) · Retina · doi:10.1097/iae.0000000000002668 · Cited by 22
Pathways of Fluid Leakage in Age-Related Macular Degeneration
Fouad, Y. A., Santina, A., Bousquet, E., Sadda, S. R., & Sarraf, D. (2023) · Retina · doi:10.1097/iae.0000000000003798 · Cited by 22
INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION
Cho, H. J., Hwang, H. J., Kim, H. S., Han, J. I., Lee, D. W., & Kim, J. W. (2017) · Retina · doi:10.1097/iae.0000000000001862 · Cited by 22
Daniel, E., Maguire, M. G., Grunwald, J. E., Toth, C. A., Jaffe, G. J., Martin, D. F., & Ying, G. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.0437 · Cited by 22
Self-citationCillà, S. D., Farruggio, S., Cocomazzi, G., Mary, D., Alkabes, M., Rossetti, L. M., Vujosevic, S., & Grossini, E. (2020) · Cellular Physiology and Biochemistry · doi:10.33594/000000212 · Cited by 21
Principal Cause of Poor Visual Acuity after Neovascular Age-Related Macular Degeneration
Okeagu, C. U., Agrón, E., Vitale, S., Domalpally, A., Chew, E. Y., & Keenan, T. D. L. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.09.025 · Cited by 21
Kim, J. H., Kim, J. W., Kim, C. G., & Lee, D. W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041145 · Cited by 21
Lindenberg, S., Nittala, M. G., Verma, A., Fitzgerald, M. E. C., Velaga, S. B., Bhisitkul, R. B., & Sadda, S. R. (2024) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2024.05.007 · Cited by 20
Pető, T., Evans, R., Reeves, B. C., Harding, S. P., Madhusudhan, S., Lotery, A. J., Downes, S. M., Balaskas, K., Bailey, C., Foss, A. J. E., et al. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.010 · Cited by 21
Lee, H., Han, K.-D., & Shin, J. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101442 · Cited by 20
Macular Atrophy in Neovascular Age-related Macular Degeneration
Berni, A., Coletto, A., Li, J., Shen, M., Bandello, F. M., Reibaldi, M., & Borrelli, E. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.01.011 · Cited by 22
Secretogranin III as a novel target for the therapy of choroidal neovascularization
LeBlanc, M. E., Wang, W., Ji, Y., Tian, H., Liu, D., Zhang, X., & Li, W. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.01.009 · Cited by 20
Wada, I., Oshima, Y., Shiose, S., Kano, K., Nakao, S., Kaizu, Y., Yoshida, S., Ishibashi, T., & Sonoda, K. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04361-8 · Cited by 19
Cho, H. J., Park, S. M., Kim, J., Nah, S. K., Lee, J., Lee, D. W., & Kim, J. W. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14631 · Cited by 19
Dubchak, E., Obasanmi, G., Zeglinski, M. R., Granville, D. J., Yeung, S. N., & Matsubara, J. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.980742 · Cited by 18
Airaldi, M., Corvi, F., Cozzi, M., Nittala, M. G., Staurenghi, G., & Sadda, S. R. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.04.012 · Cited by 16
New Therapies of Neovascular AMD—Beyond Anti-VEGFs
Yerramothu, P. (2018) · Vision · doi:10.3390/vision2030031 · Cited by 21
Daïen, V., Nguyen, V., Essex, R. W., Guymer, R. H., Arnold, J., Munk, M. R., Ćeklić, L., Gillies, M. C., & Barthelmes, D. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315055 · Cited by 17
Li, A., Rieveschl, N. B., Conti, F. F., Silva, F. Q. D. P. A., Sears, J. E., Srivastava, S. K., Ehlers, J. P., SCHACHAT, A. P., Babiuch, A. S., Kaiser, P. K., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.10.010 · Cited by 17
Self-citationBlodi, B. A., Domalpally, A., Corkery, E., Osborne, A. R., Blotner, S., Grzeschik, S. M., & Gune, S. (2023) · Ophthalmology Retina · doi:10.1016/j.oret.2023.03.004 · Cited by 17
Function-first ligandomics for ocular vascular research and drug target discovery
Rong, X., Tian, H., Yang, L., & Li, W. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.03.009 · Cited by 16
Sánchez‐Monroy, J., Nguyen, V., Puzo, M., Calvo, P., Arruabarrena, C., Monaco, P., Chilov, M. N., Keegan, D., Barthelmes, D., & Gillies, M. C. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15309 · Cited by 15
Selectively targeting disease‐restricted secretogranin III to alleviate choroidal neovascularization
Ji, L., Waduge, P., Hao, L., Kaur, A., Wan, W., Wu, Y. L., Tian, H., Zhang, J., Webster, K. A., & Li, W. (2021) · The FASEB Journal · doi:10.1096/fj.202101085rr · Cited by 15
Amarakoon, S., Ciriano, J. P. M., van den Born, L. I., Baarsma, S. G., & Missotten, T. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13774 · Cited by 15
Akkaya, S. (2020) · International Journal of Ophthalmology · doi:10.18240/ijo.2020.10.15 · Cited by 14
Mast cells promote choroidal neovascularization in a model of age-related macular degeneration
Dabouz, R., Abram, P., Rivera, J. C., & Chemtob, S. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03229-x · Cited by 16
Emerging treatments for geographic atrophy in age-related macular degeneration
Mahmoudzadeh, R., Hinkle, J. W., Hsu, J., & Garg, S. J. (2021) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000746 · Cited by 14
The Association Between Metformin Use and New-Onset ICD Coding of Geographic Atrophy
Moir, J. T., Hyman, M. J., Gonnah, R., Flores, A., Hariprasad, S. M., & Skondra, D. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.3.23 · Cited by 13
Mares, V., Reiter, G. S., Gumpinger, M., Leigang, O., Bogunović, H., Barthelmes, D., Nehemy, M. B., & Schmidt-Erfurth, U. M. (2024) · Acta Ophthalmologica · doi:10.1111/aos.16799 · Cited by 13
PROTAC based targeted degradation of LRG1 for mitigating corneal neovascularization
Zhang, J., Qi, Y., Li, Y., Zhu, F., Geng, Y., Yu, L., Xue, B., Bi, H., Jiao, Y., Min, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.063 · Cited by 13
Metadata
- Authors
- Grunwald, J. E., Pistilli, M., Daniel, E., Ying, G.-S., Pan, W., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., Maguire, M. G., & Martin, D. F.
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Cleveland Clinic (US)
- Corresponding author
- Grunwald, Juan E.
- ORCID
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 124
- Issue
- 1
- Pages
- 97-104
- ISSN
- 0161-6420 (ISSN-L)
- PMC
- PMC5234734
- OpenAlex
- W2545082692
- Cited by
- 214
- References
- 30
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 22 · 2023: 24 · 2022: 15 · 2021: 33 · 2020: 32 · 2019: 24 · 2018: 20 · 2017: 14
- FWCI
- 21.24
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, R21EY023689, U10EY017823, U10EY023530, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- geographic atrophy, age-related macular degeneration, incidence, ranibizumab, bevacizumab, choroidal neovascularization, retinal angiomatous proliferation, subretinal fluid, subretinal pigment epithelium, risk factors, anti-VEGF therapy, hemorrhage
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Female, Fluorescein Angiography, Humans, Macular Degeneration, Male, Middle Aged, Risk Factors, Incidence, Prevalence, Multivariate Analysis, Angiogenesis Inhibitors, Geographic Atrophy, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
